Company news

Neurizon Therapeutics Limited news in 2021

Neurizon Therapeutics Limited's news releases, calls and decks from 2021, newest first.

View company

Epichem Awarded Contract Extension from DNDi

December 14, 2021

Shareholder Update - Progress and Strategy

December 12, 2021

Demonstration batch of smaller size MPL tablets completed

November 30, 2021

MND & COVID-19 Phase 1 Clinical Trials On-Track

November 16, 2021

Canine phase 2b cancer trial expands to New Zealand

November 14, 2021

MPL Manufacturing and Human Trials Update

October 20, 2021

Following Extension of Survival, PAA Prepares Phase 3 Trial

October 17, 2021

Prospectus

October 1, 2021

Entitlement Options Offer

October 1, 2021

Epichem Completes Final Loan Repayment

August 30, 2021

Epichem Completes Build of OHD Benchtop Flow Reactor

August 2, 2021

Monepantel and monepantel sulfone COVID-19 anti-viral update

July 26, 2021

PharmAust and WEHI to Investigate HTLV-1 Viral Infections

July 11, 2021

Phase IIb Dog Trial Achieves Interim Clinical Endpoints

June 27, 2021

PharmAust receives ethics approval for Phase I trial in MND

June 1, 2021

Phase IIb Canine Trial Identifies Therapeutic Window for MPL

April 26, 2021

PharmAust Receives $750k R&D Tax Incentive Refund

April 7, 2021

Leiden Testing Indicates MPL SARS-CoV-2 Antiviral Activity

April 6, 2021

Update on Phase IIb Clinical Trial of Monepantel in Pet Dogs

March 29, 2021

Licensing Agreement to Develop Waste to Fuels Technology

March 22, 2021

Update on Phase IIb Clinical Trial recruitment

February 14, 2021

Epichem Awarded $200K WasteSorted e-Waste Grant

January 21, 2021

Leiden University Medical Centre Monepantel COVID-19 Testing

January 7, 2021

PAA & ONJCRI to Continue MPL Pre-clinical Investigations

January 4, 2021

Decks in 2021